STOCK TITAN

[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Clover Health Investments (CLOV) reported an insider equity transaction. The company’s General Counsel & Secretary filed a Form 4 showing a transaction on 10/15/2025 coded “F,” reflecting 57,249 Class A shares automatically withheld at $2.8 per share to satisfy taxes from RSU vesting. Following the transaction, the reporting person beneficially owns 1,405,835 shares directly.

The withholding stemmed from the vesting of 25% of RSUs granted on 10/15/2024. The remaining RSUs vest quarterly in equal 6.25% installments, with a final vesting date on 10/15/2028, subject to continued service.

Clover Health Investments (CLOV) ha comunicato una transazione azionaria interna. Il General Counsel e Segretario dell'azienda ha presentato un Modulo 4 che mostra una transazione il 15/10/2025 codificata come “F”, che riflette 57.249 azioni Classe A trattenute automaticamente per soddisfare le imposte derivanti dalla vesting degli RSU. Dopo la transazione, la persona che presenta la dichiarazione detiene direttamente in modo beneficial 1.405.835 azioni.

La trattenuta deriva dalla vesting del 25% degli RSU concessi il 15/10/2024. Le restanti RSU vestono trimestralmente in rate uguali del 6,25%, con una data di vesting finale il 15/10/2028, soggetta a continuato servizio.

Clover Health Investments (CLOV) informó una operación de acciones por parte de un insider. El Asesor Jurídico General y Secretario de la empresa presentó un Formulario 4 que muestra una transacción el 15/10/2025 codificada como “F”, que refleja 57.249 acciones Clase A retenidas automáticamente para satisfacer impuestos de la vesting de RSU. Tras la transacción, la persona reportante posee beneficios de 1.405.835 acciones directamente.

La retención se originó por la vesting del 25% de las RSU concedidas el 15/10/2024. Las RSU restantes vestirán trimestralmente en cuotas iguales de 6,25%, con una fecha de vesting final el 15/10/2028, sujeto a la continuidad del servicio.

Clover Health Investments (CLOV)가 내부자 주식 거래를 보고했습니다. 회사의 일반 counsel 겸 비서가 2025-10-15에 거래를 나타내는 Form 4를 제출했으며, RSU의 vesting로 인한 세금을 충당하기 위해 자동으로 보유된 57,249 주의 Class A 주식를 반영합니다. 거래 후 보고자는 1,405,835 주를 직접 보유합니다.

이 보유는 2024-10-15에 부여된 RSU의 25%의 vesting에서 비롯되었습니다. 남은 RSU는 매 분기 같은 비율의 6.25%로 vesting되며, 최종 vesting 날짜는 2028-10-15이고, 계속 근무 조건에 따릅니다.

Clover Health Investments (CLOV) a communiqué une opération d’actions par un initié. Le conseiller juridique général et secrétaire de l’entreprise a déposé un formulaire 4 indiquant une opération le 15/10/2025 codée “F”, reflétant 57 249 actions Classe A retenues automatiquement pour satisfaire les impôts liés à l’acquisition des RSU. Suite à l’opération, la personne déclarante détient benefício 1 405 835 actions directement.

La retenue provient de l’acquisition de 25% des RSU accordées le 15/10/2024. Les RSU restants vestent trimestriellement en installments égales de 6,25%, avec une date de vesting finale le 15/10/2028, sous réserve de la poursuite du service.

Clover Health Investments (CLOV) meldete eine Insider-Eigenkapitaltransaktion. Der General Counsel & Secretary des Unternehmens reichte ein Formular 4 ein, das eine Transaktion am 15.10.2025 mit dem Kennzeichen „F“ zeigt und 57.249 Class A-Aktien widerspiegelt, die automatisch einbehalten wurden, um Steuern aus RSU-Vesting zu erfüllen. Nach der Transaktion besitzt die meldende Person beneficial direkt 1.405.835 Aktien.

Der withholding resultierte aus dem Vesting von 25% der am 15.10.2024 gewährten RSUs. Die verbleibenden RSUs vesten vierteljährlich in gleichen 6,25%-Raten, mit einem finalen Vesting-Datum am 15.10.2028, vorbehaltlich fortgesetzter Anstellung.

استثمارات Clover Health (CLOV) أبلغت عن صفقة أسهم داخلية. قدم المستشار العام للأمانة والشؤون القانونية للشركة نموذج 4 يظهر صفقة في 15/10/2025 مُرمّزة بـ“F”، تعكس 57,249 سهماً من فئة A تُحتجز تلقائياً لتسديد الضرائب من vesting لـ RSU. بعد الصفقة، يمتلك الشخص المبلغ تقريريًا مباشرةً 1,405,835 سهماً.

نشأ الحجز من vesting لـ 25% من RSU الممنوحة في 15/10/2024. وت vest RSU المتبقية ربع سنوياً بنسباد 6.25%، مع تاريخ vesting نهائي في 15/10/2028، رهناً باستمرار الخدمة.

Clove Health Investments (CLOV) 披露了内部人权益交易。公司总法律顾问兼秘书提交的 Form 4 显示一笔发生在 2025/10/15 的交易,代码为“F”,反映出 57,249 股 A 类股份在税务上从 RSU 授予中自动扣留以缴税。交易后,申报人直接受益持有 1,405,835 股

扣留来自于于 2024/10/15 授予的 RSU 中 vesting 的 25%。剩余的 RSU 将每季度以等额的 6.25% 份额 vesting,最终 vesting 日期为 2028/10/15,前提是持续任职。

Positive
  • None.
Negative
  • None.

Clover Health Investments (CLOV) ha comunicato una transazione azionaria interna. Il General Counsel e Segretario dell'azienda ha presentato un Modulo 4 che mostra una transazione il 15/10/2025 codificata come “F”, che riflette 57.249 azioni Classe A trattenute automaticamente per soddisfare le imposte derivanti dalla vesting degli RSU. Dopo la transazione, la persona che presenta la dichiarazione detiene direttamente in modo beneficial 1.405.835 azioni.

La trattenuta deriva dalla vesting del 25% degli RSU concessi il 15/10/2024. Le restanti RSU vestono trimestralmente in rate uguali del 6,25%, con una data di vesting finale il 15/10/2028, soggetta a continuato servizio.

Clover Health Investments (CLOV) informó una operación de acciones por parte de un insider. El Asesor Jurídico General y Secretario de la empresa presentó un Formulario 4 que muestra una transacción el 15/10/2025 codificada como “F”, que refleja 57.249 acciones Clase A retenidas automáticamente para satisfacer impuestos de la vesting de RSU. Tras la transacción, la persona reportante posee beneficios de 1.405.835 acciones directamente.

La retención se originó por la vesting del 25% de las RSU concedidas el 15/10/2024. Las RSU restantes vestirán trimestralmente en cuotas iguales de 6,25%, con una fecha de vesting final el 15/10/2028, sujeto a la continuidad del servicio.

Clover Health Investments (CLOV)가 내부자 주식 거래를 보고했습니다. 회사의 일반 counsel 겸 비서가 2025-10-15에 거래를 나타내는 Form 4를 제출했으며, RSU의 vesting로 인한 세금을 충당하기 위해 자동으로 보유된 57,249 주의 Class A 주식를 반영합니다. 거래 후 보고자는 1,405,835 주를 직접 보유합니다.

이 보유는 2024-10-15에 부여된 RSU의 25%의 vesting에서 비롯되었습니다. 남은 RSU는 매 분기 같은 비율의 6.25%로 vesting되며, 최종 vesting 날짜는 2028-10-15이고, 계속 근무 조건에 따릅니다.

Clover Health Investments (CLOV) a communiqué une opération d’actions par un initié. Le conseiller juridique général et secrétaire de l’entreprise a déposé un formulaire 4 indiquant une opération le 15/10/2025 codée “F”, reflétant 57 249 actions Classe A retenues automatiquement pour satisfaire les impôts liés à l’acquisition des RSU. Suite à l’opération, la personne déclarante détient benefício 1 405 835 actions directement.

La retenue provient de l’acquisition de 25% des RSU accordées le 15/10/2024. Les RSU restants vestent trimestriellement en installments égales de 6,25%, avec une date de vesting finale le 15/10/2028, sous réserve de la poursuite du service.

Clover Health Investments (CLOV) meldete eine Insider-Eigenkapitaltransaktion. Der General Counsel & Secretary des Unternehmens reichte ein Formular 4 ein, das eine Transaktion am 15.10.2025 mit dem Kennzeichen „F“ zeigt und 57.249 Class A-Aktien widerspiegelt, die automatisch einbehalten wurden, um Steuern aus RSU-Vesting zu erfüllen. Nach der Transaktion besitzt die meldende Person beneficial direkt 1.405.835 Aktien.

Der withholding resultierte aus dem Vesting von 25% der am 15.10.2024 gewährten RSUs. Die verbleibenden RSUs vesten vierteljährlich in gleichen 6,25%-Raten, mit einem finalen Vesting-Datum am 15.10.2028, vorbehaltlich fortgesetzter Anstellung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Soares Karen

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel & Secretary
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/15/2025 F 57,249(1) D $2.8 1,405,835 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on October 15, 2025, due to the vesting of 25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Karen M. Soares 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CLOV disclose in this Form 4?

An insider reported an “F” transaction on 10/15/2025, with 57,249 shares withheld at $2.8 to cover taxes from RSU vesting.

Who is the reporting person in CLOV’s filing?

The reporting person is the company’s General Counsel & Secretary.

How many CLOV shares does the insider own after the transaction?

Beneficial ownership following the transaction is 1,405,835 shares, held directly.

What triggered the share withholding in CLOV’s Form 4?

The withholding was due to the vesting of 25% of RSUs granted on 10/15/2024.

What is the RSU vesting schedule for the remaining CLOV units?

Remaining RSUs vest quarterly in 6.25% increments, with final vesting on 10/15/2028, subject to continued service.

What does transaction code “F” indicate here?

The filing lists code F and explains shares were automatically withheld to satisfy tax obligations upon RSU vesting.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.38B
403.98M
3.88%
35.27%
9.43%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
JERSEY CITY